You are here: Industry Insights > Market News > Germany to donate all remaining AstraZeneca vaccines in Aug

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

Hot Products

Propantheline Bromide

carbomer 974P

Coenzyme Q10

Refined Fish Oil

Black Currant Extract

Hydrocortisone

Germany to donate all remaining AstraZeneca vaccines in Aug

firstwordpharmaJuly 08, 2021

Tag: AstraZeneca , COVID-19 Vaccine , COVAX

Favorites

Germany will give all its remaining AstraZeneca COVID-19 vaccine doses to less developed countries in August, as reported This is Money on Wednesday.

Germany to donate all remaining AstraZeneca vaccines in Aug

The government decided that at least 500,000 doses, representing 80%, would be given to the COVAX consortium.

Another 20% will be given directly to countries in the Western Balkans and members of the EU's Eastern Partnership - Georgia, Moldova and Ukraine - and Namibia.

Previous:Phage Display-Based Gene Delivery: A Viable Platform Technology for COVID-19 Vaccine Design and Development

Next:Stealth BioTherapeutics Joins the Rare Disease Company Coalition

InnoCare Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis

PharmaSourcesMay 16, 2024

InnoCare announced the completion of patient enrollment for the phase II clinical trial of ICP-488, a TYK2 (tyrosine kinase 2) JH2 allosteric inhibitor, for the treatment of psoriasis.

Sartorius Collaborates with Sanofi to Commercialize End-To-End Platform for Downstream Process Intensification

Biotech NewswireMay 14, 2024

Touchlight Genetics and the National Physical Laboratory (NPL) Awarded Grant to Develop Novel Gene-Length Single-Stranded Genome Editing Template

Biotech NewswireMay 10, 2024

Germany to donate all remaining AstraZeneca vaccines in Aug | Pharmasources.com

First Commercial Cell and Gene Therapy Product Manufactured at Minaris Regenerative Medicine in Allendale, NJ.

Biotech NewswireMay 09, 2024

The first commercial manufacturing run of LYFGENIA – a one-time gene therapy for the treatment of sickle cell disease developed by bluebird bio – was performed at its Allendale, NJ site.

Germany to donate all remaining AstraZeneca vaccines in Aug

Related News

InnoCare Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis

Sartorius Collaborates with Sanofi to Commercialize End-To-End Platform for Downstream Process Intensification

Touchlight Genetics and the National Physical Laboratory (NPL) Awarded Grant to Develop Novel Gene-Length Single-Stranded Genome Editing Template

First Commercial Cell and Gene Therapy Product Manufactured at Minaris Regenerative Medicine in Allendale, NJ.

You may like